The Europe neurorehabilitation devices market was valued at US$ 631.51 million in 2023 and is expected to reach US$ 1,509.96 million by 2031; it is estimated to register a CAGR of 11.5% from 2023 to 2031.
Growing Number of Clinical Studies on Neurorehabilitation Devices Drives Europe Neurorehabilitation Devices Market
Clinical studies validate the safety and effectiveness of newly developed neurorehabilitation devices. They provide evidence that neurorehabilitation devices help improve the quality of life of patients suffering from neurological diseases. These studies encourage healthcare centers to integrate these devices into their treatment programs. For instance, “Clinical Study of a Wearable Remote Rehabilitation Training System for Patients With Stroke: Randomized Controlled Pilot Trial” was published in February 2023. The clinical study aimed to design a remote intelligent rehabilitation training system based on wearable devices and human-computer interaction training tasks and evaluate its safety and efficiency.
In December 2022, a clinical trial study, “Effects of robotic rehabilitation using the Erigo device on patients with neurological injury: a systematic review and meta-analysis of randomized clinical trials,” was published. The trial studied the effects of the Erigo robotic rehabilitation device on patients with neurological injury based on parameters such as safety, muscle strength, spasticity, functionality, gait/balance, and changes in the level of consciousness. The study concluded that Erigo, as a robotic rehabilitation device, is safe for patients with acquired brain injury and can reduce spasticity in patients with stroke.
Thus, the increasing number of clinical studies on neurorehabilitation devices favors the growth of the market worldwide.
Europe Neurorehabilitation Devices Market Overview
The Ruhr- Universitandaumlt Bochum report revealed that about 270,000 people sustain traumatic brain injuries (TBIs) in Germany annually, and it is highly prevalent among those aged 65 years due to gait imbalance. Therefore, the rising frequency of TBI and other neurological conditions has led to the development of innovative products through strategic approaches. In 2024, Insightec, a pioneer and global leader in focused ultrasound, is pleased to announce that its transcranial MR-guided focused ultrasound (MRgFUS) has been granted NUB status 1 for the treatment of essential tremor (ET) in Germany. This significant milestone is set to improve patient access to cutting-edge, essential tremor treatments within the German healthcare system. Additionally, the major market players and hospitals are involved in the development of innovative products and therapies for neurorehabilitation. For Instance, neurorehabilitation centers in Germany focused on delivering measurable recoveries by using robotics-based treatments. Advanced robotics and other technologies are effective because they engage the brain differently than traditional methods. They intensify effort and provide data to immediately adapt treatment in real time. TRAINM is one such Nero rehab clinic in Germany providing these services. Thus, above mentioned factors are expected to fuel market growth in the coming years.
Europe Neurorehabilitation Devices Market Revenue and Forecast to 2031 (US$ Million)
Strategic insights for the Europe Neurorehabilitation Devices provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Neurorehabilitation Devices refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.Europe Neurorehabilitation Devices Strategic Insights
Europe Neurorehabilitation Devices Report Scope
Report Attribute
Details
Market size in 2023
US$ 631.51 Million
Market Size by 2031
US$ 1,509.96 Million
Global CAGR (2023 - 2031)
11.5%
Historical Data
2021-2022
Forecast period
2024-2031
Segments Covered
By Product Type
By Application
By End User
Regions and Countries Covered
Europe
Market leaders and key company profiles
Europe Neurorehabilitation Devices Regional Insights
Europe Neurorehabilitation Devices Market Segmentation
The Europe neurorehabilitation devices market is categorized into product type, application, end user, and country.
By product type, the Europe neurorehabilitation devices market is segmented into neurorobotic system, brain computer interface, non-invasive stimulators, and wearable devices. The brain computer interface segment held the largest share of the Europe neurorehabilitation devices market share in 2023.
In terms of application, the Europe neurorehabilitation devices market is segmented into stroke, traumatic brain injury, spinal cord injury, Parkinson's disease, cerebral palsy, and others. The stroke segment held the largest share of the Europe neurorehabilitation devices market share in 2023.
By end user, the Europe neurorehabilitation devices market is segmented into rehabilitation centers, hospitals & clinics, and home care. The hospitals & clinics segment held the largest share of the Europe neurorehabilitation devices market share in 2023.
Based on country, the Europe neurorehabilitation devices market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany segment held the largest share of Europe neurorehabilitation devices Market in 2023.
Abbott Laboratories; BIONIK; BioXtreme Ltd; Blackrock Microsystems Inc; Ekso Bionics Holdings Inc; EMOTIV; Hocoma AG; Medtronic Plc; Renishaw Plc; and Tyromotion GmbH are some of the leading companies operating in the Europe neurorehabilitation devices market.
The Europe Neurorehabilitation Devices Market is valued at US$ 631.51 Million in 2023, it is projected to reach US$ 1,509.96 Million by 2031.
As per our report Europe Neurorehabilitation Devices Market, the market size is valued at US$ 631.51 Million in 2023, projecting it to reach US$ 1,509.96 Million by 2031. This translates to a CAGR of approximately 11.5% during the forecast period.
The Europe Neurorehabilitation Devices Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Neurorehabilitation Devices Market report:
The Europe Neurorehabilitation Devices Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Neurorehabilitation Devices Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Neurorehabilitation Devices Market value chain can benefit from the information contained in a comprehensive market report.